Reaven GM. Insulin resistance and human disease: a short history. Journal of basic and clinical physiology and pharmacology. 1998; 9(2-4): 387-406.
Silfen ME , Denburg MR , Manibo AM , Lobo RA , Jaffe R , Ferin M , et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003; 88:4682-4688
 Levy-Marchal C, Arslanian S, Cutfield W, et al. Insulin resistance in children: consensus, perspective, and future directions. The Journal of Clinical Endocrinology & Metabolism. 2010; 95(12): 5189-5198.
LeeJM, OkumuraMJ, DavisMM, HermanWH, GurneyJG. Prevalence and determinants of insulin resistance among US adolescents: a population-based study. Diabetes Care. 2006 ; 29:2427-2432.
Caprio S, Perry R, Kursawe R. Adolescent obesity and insulin resistance: roles of ectopic fat accumulation and adipose inflammation. Gastroenterology. 2017; 152(7): 1638-1646.
Solà E, Kerbert AJC, Verspaget HW, et al. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. Journal of hepatology. 2016; 65(5): 914-920.
Barchetta I, Enhörning S, Cimini FA, et al. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity. BMC medicine. 2019; 17(1): 85.
Riva M, Nitert M D, Voss U, et al. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell and tissue research. 2011; 346(3): 393-405.
Aydin S. Multi-functional peptide hormone NUCB2/nesfatin-1. Endocrine. 2013; 44(2): 312-325.
Stengel A, Taché Y. Role of brain NUCB2/nesfatin-1 in the regulation of food intake. Current pharmaceutical design. 2013; 19(39): 6955-6959.
Ramesh N, Mohan H, Unniappan S. Nucleobindin-1 encodes a nesfatin-1-like peptide that stimulates insulin secretion. General and comparative endocrinology. 2015; 216: 182-18
Khalili S, Khaniani M S, Afkhami F, et al. NUCB2/Nesfatin-1: a potent meal regulatory hormone and its role in diabetes. Egyptian Journal of Medical Human Genetics. 2017; 18(2): 105-109.
Mohan H, Unniappan S. Ontogenic pattern of nucleobindin-2/nesfatin-1 expression in the gastroenteropancreatic tissues and serum of Sprague Dawley rats. Regulatory peptides. 2012; 175(1-3): 61-69.
Enhörning S, Wang T J, Nilsson P M, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010; 121(19): 2102.
Rothermel J, Kulle A, Holterhus PM, et al. Copeptin in obese children and adolescents: relationships to body mass index, cortisol and gender. Clinical endocrinology. 2016; 85(6): 868-873.
Tenderenda-Banasiuk E, Wasilewska A, Filonowicz R, et al. Serum copeptin levels in adolescents with primary hypertension. Pediatric Nephrology. 2014; 29(3): 423-429.
Abaci A, Catli G, Anik A, et al. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatric diabetes. 2013; 14(3): 189-195.
Anwar GM, Yamamah G, Ibrahim A, et al. Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance. Regulatory peptides. 2014; 188: 21-24.
Li H, Ji C, Zong X, Zhang YQ. Body mass index growth curves for Chinese children and adolescents aged 0 to 18 years. Chin J Pediatr. 2009; 47: 493-498.
Tanner JM. Growth and maturation during adolescence. Nutr Rev. 1981; 39(2): 43-55.
Andrade MI, Oliveira JS, Leal VS, Lima NM, Costa EC, Aquino NB, et al. Identification of cutoff points for Homeostatic Model Assessment for Insulin Resistance index in adolescents: systematic review. Rev Paul Pediatr. 2016; 34(2): 234-42.
Gallagher E J, LeRoith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine. 2010; 77(5): 511-523.
Simpson K, Parker J, Plumer J, Bloom S. CCK, PYY and PP: the control of energy balance. Handb Exp Pharmacol. 2012; 209: 209–230.
Ramanjaneya M, Chen J, Brown JE et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology. 2010; 151:3169–3180.
Abaci A, Catli G, Anik A, et al. The relation of serum nesfatin‐1 level with metabolic and clinical parameters in obese and healthy children. Pediatric diabetes. 2013; 14(3): 189-195.
Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumfer circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol. 1994;73:460-468.
Ashwell M, Cole TJ, Dixon AK. Ratio of waist circumference to height is strong predictor of intra-abdominal fat. Br. Med. J. 1996;313(7056): 559-560.
Ari M, Ozturk OH, Bez Y, Oktar S, Erduran D. High plasma nesfatin-1 level in patients with major depressive disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2011; 35: 497-500
Bo ttner A, Kratzsch J, Mu ller G, Kapellen TM, Blu her S, Keller E, at al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab. 2004; 89:4053-4061
Bastard J P, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. European cytokine network. 2006; 17(1): 4-12.
Enhörning S, Struck J, Wirfält E, et al. Plasma copeptin, a unifying factor behind the metabolic syndrome. The Journal of Clinical Endocrinology & Metabolism. 2011; 96(7): E1065-E1072.
Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012; 120: 91-95.
Tan BK, Hallschmid M, Kern W et al. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/nucb-2, in obese human: evidence of nesfatin-1/nucb-2 resistance and implications for obesity treatment. JCEM. 2011; 96: E669-E673.
 Karbek B, Ozbek M, Karakose M, Topaloglu O, Bozkurt NC, Cakir E, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. J Ovarian Res. 2014;7:31.
 Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121:2102-2108.
Saleem U, Khaleghi M, Morgenthaler N G, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. The Journal of Clinical Endocrinology & Metabolism. 2009;94(7): 2558-2564.